A Practical Algorithmic Approach to the Diagnosis and Management of Solitary Pulmonary Nodules. Part 2: Pretest Probability and Algorithm
|
|
- Alberta Andrews
- 6 years ago
- Views:
Transcription
1 CHEST Special Features A Practical Algorithmic Approach to the Diagnosis and Management of Solitary Pulmonary Nodules Part 2: Pretest Probability and Algorithm Vishal K. Patel, MBBS ; Sagar K. Naik, MBBS ; David P. Naidich, MD, FCCP ; William D. Travis, MD, FCCP ; Jeremy A. Weingarten, MD, FCCP ; Richard Lazzaro, MD ; David D. Gutterman, MD, FCCP ; Catherine Wentowski, MD ; Horiana B. Grosu, MD ; and Suhail Raoof, MBBS, FCCP In this second part of a two-part series, we describe an algorithmic approach to the diagnosis of the solitary pulmonary nodule (SPN). An essential aspect of the evaluation of SPN is determining the pretest probability of malignancy, taking into account the significant medical history and social habits of the individual patient, as well as morphologic characteristics of the nodule. Because pretest probability plays an important role in determining the next step in the evaluation, we describe various methods the physician may use to make this determination. Subsequently, we outline a simple yet comprehensive algorithm for diagnosing a SPN, with distinct pathways for the solid and subsolid SPN. CHEST 2013; 143(3): Abbreviations: GGN 5 ground glass nodule; FDG 5 18 F-2-deoxy-2-fluoro- d -glucose; SPN 5 solitary pulmonary nodule practical diagnostic algorithm for approaching the A solitary pulmonary nodule (SPN), stratifying clinical risk factors in a standardized manner and blending this information with radiologic clues, would point the physician toward a benign or malignant cause. 1-7 Such an approach would be expected to spare patients with benign causes the morbidity and cost associated with invasive tissue sampling and, at the same time, guide the physician toward recommending invasive tests for the nodules likely to be malignant. Calculation of Pretest Probability The clinical and radiologic features described in Part 1 (see page 825) 8 can individually provide clues Manuscript received June 12, 2012; revision accepted November 1, Affiliations: From the New York Methodist Hospital (Drs Patel, Naik, Weingarten, Lazzaro, Wentowski, Grosu, and Raoof), Brooklyn, NY; New York University Langone Medical Center (Dr Naidich), New York, NY; Memorial Sloan-Kettering Cancer Center (Dr Travis), New York, NY; and Medical College of Wisconsin (Dr Gutterman), Milwaukee, WI. Correspondence to: Suhail Raoof, MBBS, FCCP, New York Methodist Hospital, Department of Pulmonary and Critical Care, 506 Sixth St, Brooklyn, NY 11215; suhailraoof@gmail.com as to whether a given SPN is benign or malignant However, assimilating all these factors and assigning the weight of probability of malignancy to each factor, and coming up with the approximate probability of malignancy, is an onerous task. Let us take, for example, a 65-year-old patient with a 20-pack-year smoking history who is found to have a 3-cm noncalcified SPN with lobulated borders in the right upper lobe ( Fig 1 ). The physician is faced with the task of calculating the probability of malignancy in this nodule. If the probability is low, the physician is likely to recommend follow-up of this SPN with serial CT scans. On the other hand, if the probability of malignancy is moderate or high, the patient should be referred for further testing or tissue sampling. How consistent are physicians in stratifying the malignant potential of a SPN? In the instance cited, the range of pretest probability was calculated by showing the same image on the same computer screen to 44 physicians (internists and pulmonologists in academic and private practice 2013 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details. DOI: /chest Special Features
2 Figure 1. Pulmonary varix. in a community hospital in New York). The range was found to be 2% to 95% (unpublished data). Although experienced physicians routinely make these judgments by gestalt in day-to-day practice, standardized methods have been developed to calculate the probability of the malignancy of a SPN. 17 Bayesian analysis is one such approach. Likelihood ratios for malignancy are assigned to each clinical and radiologic feature by dividing the probability of finding a particular feature in patients with malignant nodules by the probability of finding the same feature in patients with benign nodules. The odds of malignancy can then be calculated by multiplying the likelihood ratios for each individual clinical and radiologic feature by the prior odds of malignancy. Probability of malignancy can then be calculated easily from the odds. A number of authors developed this approach during the 1970s and 1980s, but Gurney et al 24,25 provided the most rigorous test. They derived likelihood ratios from a database of 3,858 patients and then validated the model by comparing it with subjective clinical assessments. Following a review of the literature current at that time, they calculated likelihood ratios for age, smoking history, history of previous malignancy, hemoptysis, size of the SPN, location, edge characteristics, calcification, growth rate, and cavity wall thickness. Needless to say, these calculations were only as accurate as the studies that were used to glean the data. Subsequently, a total of 66 patients with SPNs were evaluated for the probability of malignancy by four radiologists with an average experience of 16 years, yielding an accuracy of 62.5% and an error rate of 37%. When the previously determined Bayesian analysis was employed by a separate set of radiologists with far less experience, the accuracy and error rates were much better, at 77.5% and 15.5% respectively, with fewer false-negative results. A convenient and reliable way of performing this assessment is by using a calculator available online at under the tab Practice. This calculator takes into account the likelihood ratios from a list of clinical and radiologic factors ( Table 1 ) and generates a percentage probability of malignancy. Based on this calculator, the pretest probability of malig nancy in the lesion described in the previous paragraph is 95%. Interestingly, only 66% of the respondents in our survey correctly identified the pretest probability of malignancy as 60%. Swensen et al 26 employed multivariate regression analysis in an attempt to account for the correlation and interaction among various clinical and radiologic risk factors. They derived their model from a cohort of 419 patients with SPNs detected on chest radiograph and identified risk factors as delineated in Table 1. This prediction model is described by the following equation: x x cancer diameter spiculation location Probability of malignancy e 1 e x age smoke where e 5 the natural logarithm, age is the patient s age in years, smoke 5 1 if the patient is a current or former smoker (otherwise, smoke 5 0), diameter is the diameter of the nodule in millimeters, spiculation 5 1 if the edge of the nodule has spicules (otherwise, spiculation 5 0), and location 5 1 if the nodule is located in an upper lobe (otherwise, location 5 0). The model Table 1 Calculation of Probability of Malignancy Source/Reference Factors Taken Into Consideration to Determine the Probability of Malignancy 1. Age 2. Smoking (ever vs never and pack-y) 3. Hemoptysis 4. History of prior malignancy 5. Nodule diameter 6. Location 7. Edge characteristics 8. Growth rate 9. Cavity wall thickness 10. Calcification 11. Contrast enhancement on CT scan. 15 HU 12. PET scan Swensen et al Age 2. Smoking history (ever vs never) 3. History of previous malignancy. 5 y ago 4. Presence of spiculation 5. Upper lobe location Gould et al Age 2. Smoking history (ever vs never) 3. Nodule diameter 4. Time since quitting smoking HU 5 Hounsfield unit. journal.publications.chestnet.org CHEST / 143 / 3 / MARCH
3 was then validated on separate groups of patients showing excellent calibration of the prediction model. 26,28 Additionally, the area under the curve of the prediction model was not statistically different from PET scan results. These scan results, when added to the predicted probability calculated by the model, improved the area under the curve by 13.6% (95% CI, 6-21; P ). Although this Mayo Clinic model yielded an excellent receiver-operating characteristic curve ( ), it had several important limitations: (1) Patients who had been given a diagnosis of any cancer, including lung cancer, in the past 5 years were excluded (as discussed previously, a history of malignancy confers a significant risk of a new SPN being malignant, whether metastatic or a new lung primary, and excluding these patients from the calculation would therefore potentially underestimate the probability of malignancy); (2) the model was developed in a cohort of patients with lung nodules who were originally managed more than 20 years previously at a single tertiary care center in the midwestern United States, thereby limiting the model s generalizability; and (3) the prevalence of malignancy was relatively low (23%), and in 12% of patients a final diagnosis was not determined. To address these limitations, Gould et al 27 studied a geographically diverse sample of 375 veterans with a high prevalence of malignant SPNs (54%). This study again identified independent predictors of malignancy by using multivariate regression analysis ( Table 1 ). Interestingly, upper lobe location was not found to be an independent predictor of malignancy. Notable limitations to this VA model are as follows: (1) SPN, 7 mm in diameter were excluded from the study; (2) the study sample consisted primarily of older white men, thereby limiting the generalizability of the model to female patients and patients of other ethnicities; (3) information about nodule morphology on CT chest scans was not taken into account (instead of definitive nodule morphology characteristics, radiologists were asked to rate each SPN on a five-point scale between definitely benign and definitely malignant based on chest roentgenogram morphology; this characterization was taken as a surrogate marker for spiculation. A definitely malignant nodule morphology on chest roentgenogram did not attain statistical significance as an independent predictor for malignancy, possibly because of the limited resolution of the chest roentgenogram images. A spiculated nodule should, thus, be considered high probability for malignancy even if the pretest probability calculated by the VA model suggests otherwise); and (4) the model may not be well calibrated for use in populations in which the prevalence of malignancy is much lower or higher than in this study. Physicians would therefore have to carefully consider the prevalence of malignancy in their practice setting when choosing between the two models. A comparison of these two models in a sample of 151 patients with SPNs 7 to 30 mm in size demonstrated no statistically significant difference in the receiver-operating characteristic curves, suggesting that both models were sufficiently accurate to guide clinical decision making in patients with SPNs. 17 Regardless of the model used, an assessment must then be made as to whether the calculated pretest probability of malignancy is sufficient to guide clinical decision-making (the observe vs excise dilemma presented in the previous example), or whether further imaging studies are needed to give a clearer picture as to the probability of malignancy. These imaging studies are discussed in the following sections. Practical Algorithmic Approach to the SPN To consolidate the preceding discussion into a logical sequence of steps, we propose a practical algorithm for approaching a SPN ( Fig 2 ) detected on chest roentgenogram or CT chest scan. Step 1 The first step in the evaluation of a SPN detected on chest roentgenogram is to review a previous chest roentgenogram or CT scan to assess the growth rate. A volume doubling time 2 years or a benign pattern of calcification suggests the SPN is benign and requires no further workup. However, one should be cognizant that a malignant subsolid nodule may have a doubling time 2 years, as mentioned earlier. Step 2 The second step is to decide whether the SPN is solid or subsolid. A CT chest scan with thin sections through the nodule is strongly recommended for precise characterization of the lesions. Consideration should be given to the use of low-dose techniques for this purpose as well as for all subsequent follow-up CT examinations when needed. Step 3 Evaluation of solid nodules is discussed in algorithm 2. See Figure 3 for details. Step 4 Subsolid nodules are an exception to the volume doubling rule, and are discussed separately in algorithm 3. See Figure 4 for details. 842 Special Features
4 Figure 2. Algorithm for initial detection of SPN. CXR 5 chest radiograph; SPN 5 solitary pulmonary nodule. Evaluation of the Solid SPN Step 5 A solid SPN of 8 mm in diameter, given a low pretest probability, can be followed as per the recommendations of the Fleischner Society. 9 Step 6 A solid SPN. 8 mm in diameter would require an assessment of the pretest probability of lung cancer, keeping in mind the clinical and morphologic considerations elaborated on previously. Step 7 If the pretest probability of malignancy is calculated to be very low (arbitrarily, 5%), serial observation as per the Fleischner Society recommendations is adequate. Step 8 If the calculated pretest probability of malignancy is high (arbitrarily. 60%), the patient should proceed directly to tissue diagnosis if clinically feasible (without unacceptably high risk) and in accordance with the patient s preference. Transthoracic needle aspiration, transbronchial biopsy with or without electromagnetic navigation technology, or surgical biopsy by video-assisted thoracoscopic surgery may be employed, based on the size and location of the SPN. The choice of diagnostic modality must be center specific and physician specific; peripheral lesions are often easily accessible in a center with strong interventional radiology, whereas centers that use advanced bronchoscopic techniques may prefer navigational bronchos copy for amenable peripheral lesions. Other centers may prefer a surgical diagnostic modality; in such an instance, a PET scan may be useful for preoperative staging and may help the surgeon decide which areas to biopsy. Lack of uptake on PET scan would not be a reason to defer tissue sampling. Step 9 For the intermediate range of risk (5%-60%), the judicious use of an 18 F-2-deoxy-2-fluoro- d -glucose (FDG)-PET scan should be made, with an integrated PET-CT scan used whenever possible. The sensitivity and specificity of the FDG-PET scan in detecting malignancy in a SPN, or indirectly suggesting malignancy via mediastinal lymph node involvement or distant metastases, are high enough to warrant a tissue diagnosis, if the test is positive. Solid SPNs with negative PET scans can be followed with serial CT chest scans according to the American College of Chest Physicians evidence-based clinical guidelines (3, 6, 12, and 24 months). 29 journal.publications.chestnet.org CHEST / 143 / 3 / MARCH
5 Figure 3. Algorithm for evaluation of solid SPN. TBBx 5 transbronchial biopsy; TTNA 5 transthoracic needle aspiration. See Figure 2 legend for expansion of other abbreviations. Evaluation of Subsolid SPN Step 5 In the event that the initial CT chest scan reveals a subsolid SPN, a different approach is warranted, which we have modified from Godoy and Naidich 30 and the recent Fleischner Society guideline. 31 For the subsolid nodule, the initial step is to determine whether the SPN is a pure ground glass nodule (GGN), or a mixture of ground-glass and solid components. Step 6 Controversy surrounds the management of subsolid nodules because of a paucity of data. Various expert opin ions exist in the literature but the consensus is that the SPN be managed conservatively. Pure GGNs 5 mm in size do not require further follow-up. Pure GGNs. 5 mm in size should be followed with a repeat CT chest scan in 3 months to ascertain if the lesions have resolved spontaneously. A case-by-case evaluation must then be made regarding the decision for invasive tissue biopsy if the SPN persists. If the lesion has not changed in size, conservative management is recommended, with at least three consecutive annual thin-section CT scans required to document stability. Although data to support an optimal duration of conservative follow-up are lacking, the follow-up period of 3 years takes into consideration the slow doubling times of adenocarcinomas. Accurate assessment of inter val change in the size of these nodules is best accomplished by comparing thin-section CT scans, 844 Special Features
6 Figure 4. Algorithm for evaluation of subsolid SPN. GGN 5 ground glass nodule. See Figure 2 legend for expansion of other abbreviations. and by closely monitoring any change in the attenuation of lesions. Either change should be interpreted as indicative of possible malignancy, and in most cases, surgical resection should be strongly considered. PET-CT scanning is not of adequate diagnostic value, either for differentiating benign from either premalignant or invasive lesions or for staging malignant lesions, and is, therefore, best avoided in this setting. Finally, SPNs with mixed solid and ground-glass components of any size represent malignancy often enough to warrant close observation. A PET-CT scan may be considered at this stage, especially if the solid component is. 8 mm in diameter. Based upon the results of this test, biopsy, surgical resection, or surveillance with serial CT scans may be performed. It is important to point out that if the nodule changes in size or characteristics, the likelihood of malignancy is high and surgical resection should be contemplated. Conclusion In this article, we advocate calculating the pretest probability of malignancy in a SPN. Such a practice may minimize the interobserver variability in estimating the risk of malignancy and may, in turn, steer the physician to more strategic management pathways. The algorithmic approach begins by separating subsolid from solid nodules. For SPNs, 8 mm in size and for those. 8 mm in size with a low probability of malignancy, serial CT scans are recommended (Fleischner Society and American College of Chest Physicians guidelines, respectively). The high-risk SPN. 8 mm in size should be resected or should undergo tissue diagnosis; obviously, patient preference and the sever ity of comorbid medical conditions must be considered prior to any intervention. An integrated FDG-PET scan should be considered for a SPN with an intermediate risk of malignancy. If activ ity is picked up on the FDG-PET scan, the nodule should be resected. On the other hand, a pure GGN 5 mm in diameter does not require further workup. Those. 5 mm require serial CT scans for a duration. 2 years. And finally, subsolid GGNs. 5 mm that persist beyond 3 months should undergo PET-CT scan or be considered for surgical resection. Although many questions remain at this time, we hope this practical algorithmic approach to evaluating these nodules journal.publications.chestnet.org CHEST / 143 / 3 / MARCH
7 can help physicians navigate toward a definitive diagnosis in a timely, reliable, and resource-conscious fashion. Acknowledgments Financial/nonfinancial disclosures: The authors have reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article. Other contributions: The authors thanks Patrice Balistreri, adminstrative assistant, for her invaluable clerical assistance. References 1. Nathan MH, Collins VP, Adams RA. Differentiation of benign and malignant pulmonary nodules by growth rate. Radiology ;79: Garland LH, Coulson W, Wollin E. The rate of growth and apparent duration of untreated primary bronchial carcinoma. Cancer ;16: Steele JD, Buell P. Asymptomatic solitary pulmonary nodules. Host survival, tumor size, and growth rate. J Thorac Cardiovasc Surg ;65(1): Weiss W. Tumor doubling time and survival of men with bronchogenic carcinoma. Chest ;65(1): Friberg S, Mattson S. On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol ;65(4): Bach PB, Silvestri GA, Hanger M. Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest ;132(suppl 3):69S-77S. 7. Soubani AO. The evaluation and management of the solitary pulmonary nodule. Postgrad Med J ;84(995): Patel VK, Naik SK, Naidich DP, et al. A practical algorithm approach to the diagnosis and management of solitary pulmonary nodules: part 1: radiologic characteristics and imaging modalities. Chest ;143(3): MacMahon H, Austin JH, Gamsu G, et al ; Fleischner Society. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology ;237(2): Swensen SJ, Viggiano RW, Midthun DE, et al. Lung nodule enhancement at CT: multicenter study. Radiology ; 214 (1): Furuya K, Murayama S, Soeda H, et al. New classification of small pulmonary nodules by margin characteristics on highresolution CT. Acta Radiol ;40(5): Seemann MD, Seemann O, Luboldt W, et al. Differentiation of malignant from benign solitary pulmonary lesions using chest radiography, spiral CT and HRCT. Lung Cancer ; 29 (2): Zwirewich CV, Vedal S, Miller RR, Müller NL. Solitary pulmonary nodule: high-resolution CT and radiologic-pathologic correlation. Radiology ;179(2): Siegelman SS, Zerhouni EA, Leo FP, Khouri NF, Stitik FP. CT of the solitary pulmonary nodule. AJR Am J Roentgenol ;135(1): Huston J III, Muhm JR. Solitary pulmonary opacities: plain tomography. Radiology ;163(2): Ikehara M, Saito H, Kondo T, et al. Comparison of thin-section CT and pathological findings in small solid-density type pulmonary adenocarcinoma: prognostic factors from CT findings. Eur J Radiol ;81 (1 ): Schultz EM, Sanders GD, Trotter PR, et al. Validation of two models to estimate the probability of malignancy in patients with solitary pulmonary nodules. Thorax ;63 (4 ): Templeton AW, Jansen C, Lehr JL, Hufft R. Solitary pulmonary lesions. Computer-aided differential diagnosis and evaluation of mathematical methods. Radiology ;89 (4 ): Wojtowicz J, Grala B, Pietraszkiewicz, L. A trial of differential diagnosis of solitary pulmonary foci on the basis of Bayes s equation with the use of electronic digital cornputers. Pol Rev Radiol NucI Med ;34 : Alperovitch A, Lellouch J. Value of computer diagnosis of a single thoracic X-ray circular opacity. Biomedicine ;20 (1 ): Rotte KH, Meiske W. Results of computer-aided diagnosis of peripheral bronchial carcinoma. Radiology ; 125 ( 3 ): Edwards FH, Schaefer PS, Callahan S, Graeber GM, Albus RA. Bayesian statistical theory in the preoperative diagnosis of pulmonary lesions. Chest ;92 (5 ): Edwards FH, Schaefer PS, Cohen AJ, et al. Use of artificial intelligence for the preoperative diagnosis of pulmonary lesions. Ann Thorac Surg ;48 (4 ): Gurney JW. Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis. Part I. Theory. Radiology ;186 (2 ): Gurney JW, Lyddon DM, McKay JA. Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis. Part II. Application. Radiology ;186 (2 ): Swensen SJ, Silverstein MD, Ilstrup DM, Schleck CD, Edell ES. The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. Arch Intern Med ;157 (8 ): Gould MK, Ananth L, Barnett PG ; Veterans Affairs SNAP Cooperative Study Group. A clinical model to estimate the pretest probability of lung cancer in patients with solitary pulmonary nodules. Chest ;131 (2 ): Herder GJ, van Tinteren H, Golding RP, et al. Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-fluorodeoxyglucose positron emission tomography. Chest ;128 (4 ): Gould MK, Fletcher J, Iannettoni MD, et al ; American College of Chest Physicians. Evaluation of patients with pulmonary nodules: when is it lung cancer? ACCP evidencebased clinical practice guidelines (2nd edition). Chest ; 132(suppl 3):108S-130S. 30. Godoy MC, Naidich DP. Subsolid pulmonary nodules and the spectrum of peripheral adenocarcinomas of the lung: recommended interim guidelines for assessment and management. Radiology ;253 (3 ): Naidich DP, Bankier AA, Macmahon H, et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology ;266 (1 ): Special Features
A Clinical Model To Estimate the Pretest Probability of Lung Cancer in Patients With Solitary Pulmonary Nodules*
Original Research CANCER A Clinical Model To Estimate the Pretest Probability of Lung Cancer in Patients With Solitary Pulmonary Nodules* Michael K. Gould, MD, MS, FCCP; Lakshmi Ananth, MS; and Paul G.
More informationComparison of three mathematical prediction models in patients with a solitary pulmonary nodule
Original Article Comparison of three mathematical prediction models in patients with a solitary pulmonary nodule Xuan Zhang*, Hong-Hong Yan, Jun-Tao Lin, Ze-Hua Wu, Jia Liu, Xu-Wei Cao, Xue-Ning Yang From
More informationCT Screening for Lung Cancer for High Risk Patients
CT Screening for Lung Cancer for High Risk Patients The recently published National Lung Cancer Screening Trial (NLST) showed that low-dose CT screening for lung cancer reduces mortality in high-risk patients
More informationValidation of two models to estimate the probability of malignancy in patients with solitary pulmonary nodules
1 Stanford School of Medicine, Stanford, California, USA; 2 Duke University, Durham, North Carolina, USA; 3 Medical University of South Carolina, Charleston, South Carolina, USA; 4 VA Palo Alto Health
More informationThe solitary pulmonary nodule: Assessing the success of predicting malignancy
The solitary pulmonary nodule: Assessing the success of predicting malignancy Poster No.: C-0829 Congress: ECR 2010 Type: Scientific Exhibit Topic: Chest Authors: R. W. K. Lindsay, J. Foster, K. McManus;
More informationEvidence based approach to incidentally detected subsolid pulmonary nodule. DM SEMINAR July 27, 2018 Harshith Rao
Evidence based approach to incidentally detected subsolid pulmonary nodule DM SEMINAR July 27, 2018 Harshith Rao Outline Definitions Etiologies Risk evaluation Clinical features Radiology Approach Modifications:
More informationOBJECTIVES. Solitary Solid Spiculated Nodule. What would you do next? Case Based Discussion: State of the Art Management of Lung Nodules.
Organ Imaging : September 25 2015 OBJECTIVES Case Based Discussion: State of the Art Management of Lung Nodules Dr. Elsie T. Nguyen Dr. Kazuhiro Yasufuku 1. To review guidelines for follow up and management
More informationExisting General Population Models Inaccurately Predict Lung Cancer Risk in Patients Referred for Surgical Evaluation
Existing General Population Models Inaccurately Predict Lung Cancer Risk in Patients Referred for Surgical Evaluation James M. Isbell, MD, MSCI, Stephen Deppen, MA, MS, Joe B. Putnam, Jr, MD, Jonathan
More informationAmerican College Of Radiology ACR Appropriateness Criteria WORK-UP OF THE SOLITARY PULMONARY NODULE
This document is provided to you by the American College of Radiology. We strive to deliver this information in a convenient and effective manner. After you finish reviewing the criteria, please provide
More informationLUNG NODULES: MODERN MANAGEMENT STRATEGIES
Department of Radiology LUNG NODULES: MODERN MANAGEMENT STRATEGIES Christian J. Herold M.D. Department of Biomedical Imaging and Image-guided Therapy Medical University of Vienna Vienna, Austria Pulmonary
More informationDENOMINATOR: All final reports for CT imaging studies with a finding of an incidental pulmonary nodule for patients aged 35 years and older
Quality ID #364: Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines National Quality
More informationApproach to Pulmonary Nodules
Approach to Pulmonary Nodules Edwin Jackson, Jr., DO Assistant Professor-Clinical Director, James Early Detection Clinic Department of Internal Medicine Division of Pulmonary, Allergy, Critical Care and
More informationRodney C Richie MD FACP FCCP DBIM Texas Life and EMSI
Rodney C Richie MD FACP FCCP DBIM Texas Life and EMSI Pulmonary Nodules Well-circumscribed, radiographic opacities measuring 3 cm in diameter Surrounded by aerated lung Not associated with atelectesis
More informationAdam J. Hansen, MD UHC Thoracic Surgery
Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered
More informationLung Cancer Screening: To Screen or Not to Screen?
Lung Cancer Screening: To Screen or Not to Screen? Lorriana Leard, MD Co-Director of UCSF Lung Cancer Screening Program Vice Chief of Clinical Activities UCSF Pulmonary, Critical Care, Allergy & Sleep
More informationLearning Objectives. 1. Identify which patients meet criteria for annual lung cancer screening
Disclosure I, Taylor Rowlett, DO NOT have a financial interest /arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context
More informationMay-Lin Wilgus. A. Study Purpose and Rationale
Utility of a Computer-Aided Diagnosis Program in the Evaluation of Solitary Pulmonary Nodules Detected on Computed Tomography Scans: A Prospective Observational Study May-Lin Wilgus A. Study Purpose and
More informationLung Cancer Diagnosis for Primary Care
Lung Cancer Diagnosis for Primary Care Daniel Nader, DO, FCCP Cancer Treatment Center of America Case 1 In which of the following situations would the U.S. Preventive Services Task Force (USPSTF) recommend
More informationThoracic CT pattern in lung cancer: correlation of CT and pathologic diagnosis
19 th Congress of APSR PG of Lung Cancer (ESAP): Update of Lung Cancer Thoracic CT pattern in lung cancer: correlation of CT and pathologic diagnosis Kazuma Kishi, M.D. Department of Respiratory Medicine,
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #364: Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines National Quality
More informationPublished Pulmonary Nodule Guidelines A Synthesis
Published Pulmonary Nodule Guidelines A Synthesis Dr A Devaraj Royal Brompton Hospital London 4/28/2015 1 And very soon to be published Published ^ Pulmonary Nodule Guidelines A Synthesis Dr A Devaraj
More informationScreening for Lung Cancer: New Guidelines, Old Problems
Screening for Lung Cancer: New Guidelines, Old Problems Robert Schilz DO, PhD Associate Professor of Medicine Interim Chief of the Division of Pulmonary, Critical Care and Sleep Medicine University Hospitals
More informationGUIDELINES FOR PULMONARY NODULE MANAGEMENT : RECENT CHANGES AND UPDATES
Venice 2017 GUIDELINES FOR PULMONARY NODULE MANAGEMENT : RECENT CHANGES AND UPDATES Heber MacMahon MB, BCh Department of Radiology The University of Chicago Disclosures Consultant for Riverain Medical
More informationThe small subsolid pulmonary nodules. What radiologists need to know.
The small subsolid pulmonary nodules. What radiologists need to know. Poster No.: C-1250 Congress: ECR 2016 Type: Educational Exhibit Authors: L. Fernandez Rodriguez, A. Martín Díaz, A. Linares Beltrán,
More informationRole of CT imaging to evaluate solitary pulmonary nodule with extrapulmonary neoplasms
Original Research Article Role of CT imaging to evaluate solitary pulmonary nodule with extrapulmonary neoplasms Anand Vachhani 1, Shashvat Modia 1*, Varun Garasia 1, Deepak Bhimani 1, C. Raychaudhuri
More informationPULMONARY NODULES DETECTED INCIDENTALLY OR BY SCREENING: LOTS OF GUIDELINES BUT WHERE IS THE EVIDENCE?
PULMONARY NODULES DETECTED INCIDENTALLY OR BY SCREENING: LOTS OF GUIDELINES BUT WHERE IS THE EVIDENCE? MICHAEL K. GOULD, MD SENIOR RESEARCH SCIENTIST DIRECTOR FOR HEALTH SCIENCES & IMPLEMENTATION SCIENCE
More informationEvaluation of Individuals With Pulmonary Nodules: When Is It Lung Cancer?
CHEST Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES Evaluation of Individuals With Pulmonary Nodules: When Is It Lung Cancer? Diagnosis and Management of Lung Cancer, 3rd
More informationPulmonary Nodules. Michael Morris, MD
Pulmonary Nodules Michael Morris, MD Case 45 year old healthy male Smokes socially Normal physical exam Pre-employment screening remote +PPD screening CXR nodular opacity Case 45 year old healthy male
More informationPulmonary Nodules: When to worry, when to chill. Douglas Arenberg Associate Professor Pulmonary & Critical Care
Pulmonary Nodules: When to worry, when to chill Douglas Arenberg Associate Professor Pulmonary & Critical Care Disclosure MDCH Grant Funds to improve tobacco cessation service in the Michigan Medicine
More informationPULMONARY NODULES AND MASSES : DIAGNOSTIC APPROACH AND NEW MANAGEMENT GUIDELINES. https://tinyurl.com/hmpn2018
PULMONARY NODULES AND MASSES : DIAGNOSTIC APPROACH AND NEW MANAGEMENT GUIDELINES Heber MacMahon MB, BCh Department of Radiology The University of Chicago https://tinyurl.com/hmpn2018 Disclosures Consultant
More informationPulmonary Nodules & Masses
Pulmonary Nodules & Masses A Diagnostic Approach Heber MacMahon The University of Chicago Department of Radiology Disclosure Information Consultant for Riverain Technology Minor equity in Hologic Royalties
More informationXiaohuan Pan 1,2 *, Xinguan Yang 1,2 *, Jingxu Li 1,2, Xiao Dong 1,2, Jianxing He 2,3, Yubao Guan 1,2. Original Article
Original Article Is a 5-mm diameter an appropriate cut-off value for the diagnosis of atypical adenomatous hyperplasia and adenocarcinoma in situ on chest computed tomography and pathological examination?
More informationPET CT for Staging Lung Cancer
PET CT for Staging Lung Cancer Rohit Kochhar Consultant Radiologist Disclosures Neither I nor my immediate family members have financial relationships with commercial organizations that may have a direct
More informationThe Spectrum of Management of Pulmonary Ground Glass Nodules
The Spectrum of Management of Pulmonary Ground Glass Nodules Stanley S Siegelman CT Society 10/26/2011 No financial disclosures. Noguchi M et al. Cancer 75: 2844-2852, 1995. 236 surgically resected peripheral
More informationIndeterminate Lung Nodules in Cancer Patients: Pretest Probability of Malignancy and the Role of 18 F-FDG PET/CT
Cardiopulmonary Imaging Original Research Evangelista et al. FDG PET/CT of Malignant Lung Nodules Cardiopulmonary Imaging Original Research FOCUS ON: Laura Evangelista 1 Annalori Panunzio 2 Roberta Polverosi
More informationSmall Pulmonary Nodules: Our Preliminary Experience in Volumetric Analysis of Doubling Times
Small Pulmonary Nodules: Our Preliminary Experience in Volumetric Analysis of Doubling Times Andrea Borghesi, MD Davide Farina, MD Roberto Maroldi, MD Department of Radiology University of Brescia Brescia,
More informationCharacterization of the Solitary Pulmonary Nodule: 18 F-FDG PET Versus Nodule-Enhancement CT
PET vs CT of Solitary Pulmonary Nodules Nuclear Medicine Original Research C D E M N E U T R Y L I M C I G O F I N G Characterization of the Solitary Pulmonary Nodule: 18 F-FDG PET Versus Nodule-Enhancement
More informationIndications and methods of surgical treatment of solitary pulmonary nodule
Original Paper Indications and methods of surgical treatment of solitary pulmonary nodule John Karathanassis 1, Konstantinos Potaris 1, Aphrodite Karathanassis 2, Marios Konstantinou 1, Konstantinos Syrigos
More informationScreening Programs background and clinical implementation. Denise R. Aberle, MD Professor of Radiology and Engineering
Screening Programs background and clinical implementation Denise R. Aberle, MD Professor of Radiology and Engineering disclosures I have no disclosures. I have no conflicts of interest relevant to this
More informationGuidelines for the Management of Pulmonary Nodules Detected by Low-dose CT Lung Cancer Screening
Guidelines for the Management of Pulmonary Nodules Detected by Low-dose CT Lung Cancer Screening 1. Introduction In January 2005, the Committee for Preparation of Clinical Practice Guidelines for the Management
More informationEndobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer
Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer Dr Richard Booton PhD FRCP Lead Lung Cancer Clinician, Consultant Respiratory Physician & Speciality Director Manchester University NHS
More informationPurpose. Methods and Materials
Thin-section CT findings in peripheral lung cancer of 3 cm or smaller: are there any characteristic features for predicting tumor histology or do they depend only on tumor size? Poster No.: C-1893 Congress:
More informationPET/CT in lung cancer
PET/CT in lung cancer Andrei Šamarin North Estonia Medical Centre 3 rd Baltic Congress of Radiology 08.10.2010 Imaging in lung cancer Why do we need PET/CT? CT is routine imaging modality for staging of
More informationI appreciate the courtesy of Kusumoto at NCC for this presentation. What is Early Lung Cancers. Early Lung Cancers. Early Lung Cancers 18/10/55
I appreciate the courtesy of Kusumoto at NCC for this presentation. Dr. What is Early Lung Cancers DEATH Early period in its lifetime Curative period in its lifetime Early Lung Cancers Early Lung Cancers
More informationWith recent advances in diagnostic imaging technologies,
ORIGINAL ARTICLE Management of Ground-Glass Opacity Lesions Detected in Patients with Otherwise Operable Non-small Cell Lung Cancer Hong Kwan Kim, MD,* Yong Soo Choi, MD,* Kwhanmien Kim, MD,* Young Mog
More informationLos Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010
Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010 Self Assessment Module on Nuclear Medicine and PET/CT Case Review FDG PET/CT IN LYMPHOMA AND MELANOMA Submitted
More informationCharacterization of solitary pulmonary nodules: Use of washout characteristics at contrast-enhanced computed tomography
672 Characterization of solitary pulmonary nodules: Use of washout characteristics at contrast-enhanced computed tomography XIAO-DAN YE 1*, JIAN-DING YE 1*, ZHENG YUAN 2,3, SHENG DONG 4 and XIANG-SHENG
More informationThe Solitary Pulmonary Nodule*
The Solitary Pulmonary Nodule* ethany. Tan, MD; Kevin R. Flaherty, MD; Ella A. Kazerooni, MD; and Mark D. Iannettoni, MD, FCCP More than 150,00 patients a year present to their physicians with the diagnostic
More informationLung Cancer Risk Associated With New Solid Nodules in the National Lung Screening Trial
Cardiopulmonary Imaging Original Research Pinsky et al. Lung Cancer Risk Associated With New Nodules Cardiopulmonary Imaging Original Research Paul F. Pinsky 1 David S. Gierada 2 P. Hrudaya Nath 3 Reginald
More informationDiagnostic challenge: Sclerosing Hemangioma of the Lung. Department of Medicine, Division of Pulmonary and Critical Care, Lincoln Medical and
Diagnostic challenge: Sclerosing Hemangioma of the Lung. S. Arias M.D, R. Loganathan M.D, FCCP Department of Medicine, Division of Pulmonary and Critical Care, Lincoln Medical and Mental Health Center/Weill
More informationWhat to know and what to make of it
Lung Cancer Screening: What to know and what to make of it J. Matthew Reinersman, MD Assistant Professor of Surgery Division of Thoracic and Cardiovascular Surgery Department of Surgery University of Oklahoma
More informationNoninvasive Differential Diagnosis of Pulmonary Nodules Using the Standardized Uptake Value Index
doi: 10.5761/atcs.oa.14-00241 Original Article Noninvasive Differential Diagnosis of Pulmonary Nodules Using the Standardized Uptake Value Index Satoshi Shiono, MD, 1 Naoki Yanagawa, MD, 2 Masami Abiko,
More informationPositron Emission Tomography in Lung Cancer
May 19, 2003 Positron Emission Tomography in Lung Cancer Andrew Wang, HMS III Patient DD 53 y/o gentleman presented with worsening dyspnea on exertion for the past two months 30 pack-year smoking Hx and
More informationMANAGEMENT RECOMMENDATIONS
1 MANAGEMENT RECOMMENDATIONS 1. Adrenal masses!!!!!!! page 2 2. Liver Masses!!!!!!! page 3 3. Obstetric US Soft Markers for Aneuploidy!! pages 4-6 4. Ovarian and Adnexal Cysts!!!!! pages 7-10 5. Pancreatic
More informationDr Sneha Shah Tata Memorial Hospital, Mumbai.
Dr Sneha Shah Tata Memorial Hospital, Mumbai. Topics covered Lymphomas including Burkitts Pediatric solid tumors (non CNS) Musculoskeletal Ewings & osteosarcoma. Neuroblastomas Nasopharyngeal carcinomas
More informationUtility of PET-CT for detection of N2 or N3 nodal mestastases in the mediastinum in patients with non-small cell lung cancer (NSCLC)
Utility of PET-CT for detection of N2 or N3 nodal mestastases in the mediastinum in patients with non-small cell lung cancer (NSCLC) Poster No.: C-1360 Congress: ECR 2015 Type: Scientific Exhibit Authors:
More informationAmerican College of Radiology ACR Appropriateness Criteria
American College of Radiology ACR Criteria Radiologic Management of Thoracic Nodules and Masses Variant 1: Middle-aged patient (35 60 years old) with an incidental 1.5-cm lung nodule. The lesion was smooth.
More informationExample of lung screening
Justification of the use of CT for individual health assessment of asymptomatic people How to obtain evidence for IHA - Example of lung screening Mathias Prokop, MD PhD Professor of Radiology Radboud University
More informationMayo Clinic College of Medicine, Rochester, Minnesota, USA
The Oncologist Lung Cancer Commentary: CT Screening for Lung Cancer Caveat Emptor JAMES R. JETT,DAVID E. MIDTHUN Mayo Clinic College of Medicine, Rochester, Minnesota, USA Key Words. CT screening Early
More informationUtility of 18 F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer
Utility of F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer Ngoc Ha Le 1*, Hong Son Mai 1, Van Nguyen Le 2, Quang Bieu Bui 2 1 Department
More informationDiagnostic Correlation of Findings of Multidetector Computed Tomography and Fine Needle Aspiration Cytology in Lung Masses
RESEARCH ARTICLE Diagnostic Correlation of Findings 10.5005/jp-journals-10057-0004 of MDCT and FNAC in Lung Masses Diagnostic Correlation of Findings of Multidetector Computed Tomography and Fine Needle
More informationIn 1995, American physicians investigated an estimated 150,000 patients
Lacasse et al General Thoracic Surgery Transthoracic needle biopsy in the diagnosis of solitary pulmonary nodules: A survey of Canadian physicians Yves Lacasse, MD, MSc Julie Plante, MD Simon Martel, MD
More informationMalignant solitary pulmonary nodules: assessment of mass growth rate and doubling time at follow-up CT
Original Article Malignant solitary pulmonary nodules: assessment of mass growth rate and doubling time at follow-up CT Jingxu Li*, Tingting Xia*, Xinguan Yang, Xiao Dong, Jiamin Liang, Nanshan Zhong,
More informationSpectrum of Radiological Findings in Bronchogenic Carcinoma A Retrospective Study
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 17, Issue 01 Ver. VIII January. (2018), PP 43-59 www.iosrjournals.org Spectrum of Radiological Findings
More informationEstablishment of a mathematic model for predicting malignancy in solitary pulmonary nodules
Original Article Establishment of a mathematic model for predicting malignancy in solitary pulmonary nodules Man Zhang 1,2, Na Zhuo 3, Zhanlin Guo 2, Xingguang Zhang 4, Wenhua Liang 5,6, Sheng Zhao 7,
More informationand Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
More informationTumor Board Discussions: Case 1
Tumor Board Discussions: Case 1 David S. Ettinger, MD The Alex Grass Professor of Oncology Johns Hopkins University School of Medicine Baltimore, Maryland Case #1 50-year-old Asian female, never smoker
More informationCharles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
More informationEarly Lung Cancer Action Project: A Summary of the Findings on Baseline Screening
Early Lung Cancer Action Project: A Summary of the Findings on Baseline Screening CLAUDIA I. HENSCHKE, a DOROTHY I. MCCAULEY, b DAVID F. YANKELEVITZ, a DAVID P. NAIDICH, b GEORGEANN MCGUINNESS, b OLLI
More informationGROUP 1: Peripheral tumour with normal hilar and mediastinum on staging CT with no disant metastases. Including: Excluding:
GROUP 1: Including: Excluding: Peripheral tumour with normal hilar and mediastinum on staging CT with no disant metastases Solid pulmonary nodules 8mm diameter / 300mm3 volume and BROCK risk of malignancy
More informationLoren Ketai, MD; Mathurn Malby, BS; Kirk Jordan, MD; Andrew Meholic, MD; and Julie Locken, MD
Small Nodules Detected on Chest Radiography* Does Size Predict Calcification? Loren Ketai, MD; Mathurn Malby, BS; Kirk Jordan, MD; Andrew Meholic, MD; and Julie Locken, MD Study objectives: To determine
More informationThe Role of PET / CT in Lung Cancer Staging
July 2004 The Role of PET / CT in Lung Cancer Staging Vlad Vinarsky, Harvard Medical School Year IV Patient AM HPI: 81 yo F p/w hemoptysis x 1 month LLL lesion on CXR, not responsive to Abx 35 pack-year
More informationSCBT-MR 2015 Incidentaloma on Chest CT
SCBT-MR 2015 Incidentaloma on Chest CT Reginald F. Munden MD, DMD, MBA I have no conflicts of interest to report Incidentaloma Pulmonary Nodule Mediastinal Lymph Node Coronary Artery Calcium Incidental
More informationLow-dose CT Lung Cancer Screening Guidelines for Pulmonary Nodules Management Version 2
Low-dose CT Lung Cancer Screening Guidelines for Pulmonary Nodules Management Version 2 The Committee for Management of CT-screening-detected Pulmonary Nodules 2009-2011 The Japanese Society of CT Screening
More informationSCBT-MR 2016 Lung Cancer Screening in Practice: State of the Art
SCBT-MR 2016 Lung Cancer Screening in Practice: State of the Art Reginald F. Munden MD, DMD, MBA I have no conflicts of interest to report National Lung Cancer Screening Trial 20% lung cancer mortality
More informationSolitary Pulmonary Nodules: Detection, Characterization, and Guidance for Further Diagnostic Workup and Treatment
Jeong et al. Solitary Pulmonary Nodules Chest Imaging Perspective 057.fm 11/30/06 Yeong Joo Jeong 1,2 Chin A. Yi 1 Kyung Soo Lee 1 Jeong YJ, Yi CA, Lee KS Keywords: chest imaging, dynamic CT, lung, lung
More informationCorporate Medical Policy Electromagnetic Navigation Bronchoscopy
Corporate Medical Policy Electromagnetic Navigation Bronchoscopy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: electromagnetic_navigation_bronchoscopy 1/2010 3/2017 3/2018 9/2017
More informationLarry Tan, MD Thoracic Surgery, HSC. Community Cancer Care Educational Conference October 27, 2017
Larry Tan, MD Thoracic Surgery, HSC Community Cancer Care Educational Conference October 27, 2017 To describe patient referral & triage for the patient with suspected lung cancer To describe the initial
More informationEvaluation of Lung Cancer Response: Current Practice and Advances
Evaluation of Lung Cancer Response: Current Practice and Advances Jeremy J. Erasmus I have no financial relationships, arrangements or affiliations and this presentation will not include discussion of
More informationProjected Outcomes Using Different Nodule Sizes to Define a Positive CT Lung Cancer Screening Examination
DOI:10.1093/jnci/dju284 First published online October 20, 2014 The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
More informationRobert J. McKenna M.D. Chief, Thoracic Surgery Cedars Sinai Medical Center
You Smoke, You Get Lung Cancer, You Die: Can Screening Change this Paradigm? Robert J. McKenna M.D. Chief, Thoracic Surgery Cedars Sinai Medical Center AATS Saturday 4/28/2012 Cancer Screening Cancer
More informationResearch Article The Advantage of PET and CT Integration in Examination of Lung Tumors
Hindawi Publishing Corporation International Journal of Biomedical Imaging Volume 2007, Article ID 17131, 5 pages doi:10.1155/2007/17131 Research Article The Advantage of PET and CT Integration in Examination
More informationPercutaneous Needle Aspiration Biopsy (PCNA) of Pulmonary Lesions: Evaluation of a Reaspiration or a Rebiopsy (second PCNA) 1
Percutaneous Needle Aspiration Biopsy (PCNA) of Pulmonary Lesions: Evaluation of a Reaspiration or a Rebiopsy (second PCNA) 1 In Jae Lee, M.D., Dong Gyu Kim, M.D. 2, Ki-Suck Jung, M.D. 2, Hyoung June Im,
More informationProportion and characteristics of transient nodules in a retrospective analysis of pulmonary nodules
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Proportion and characteristics of transient nodules in a retrospective analysis of pulmonary nodules Jin-Yeong Yu 1, Boram Lee 1, Sunmi Ju 1, Eun-Young Kim
More informationUniportal video-assisted thoracoscopic surgery segmentectomy
Case Report on Thoracic Surgery Page 1 of 5 Uniportal video-assisted thoracoscopic surgery segmentectomy John K. C. Tam 1,2 1 Division of Thoracic Surgery, National University Heart Centre, Singapore;
More informationFDG-PET/CT imaging for mediastinal staging in patients with potentially resectable non-small cell lung cancer.
FDG-PET/CT imaging for mediastinal staging in patients with potentially resectable non-small cell lung cancer. Schmidt-Hansen, M; Baldwin, DR; Zamora, J 2018 American Medical Association. All Rights Reserved.
More informationORIGINAL ARTICLE. Introduction. Cancer Imaging (2012) 12(3), DOI: /
Cancer Imaging (2012) 12(3), 437 446 DOI: 10.1102/1470-7330.2012.0035 ORIGINAL ARTICLE Characterization of pulmonary lesions in patients with suspected lung cancer: computed tomography versus [ 18 F]fluorodeoxyglucose-positron
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationLUNG CANCER SCREENING
LUNG CANCER SCREENING Christopher Lettieri MD, FACP, FCCP, FAASM Pulmonary/Critical Care Consultant to the Surgeon General Professor of Medicine Walter Reed National Military Medical Center American College
More informationU"lity of Screening and Surveillance Using Nuclear Medicine Methodology. (Lung Cancer) Michael M. Graham, PhD, MD University of Iowa
U"lity of Screening and Surveillance Using Nuclear Medicine Methodology (Lung Cancer) Michael M. Graham, PhD, MD University of Iowa American Cancer Society IniBal Guideline Clinicians with access to high-
More informationA Chronology of Advancements in the Diagnosing of Lung Nodules
November 17, 2017 A Chronology of Advancements in the Diagnosing of Lung Nodules Presenter: Daniel P. Harley, MD, MSB, FACS Surgical Director of the Angelos Center for Lung Diseases 1 Pulmonary Nodules
More informationComparison of dual energy subtraction chest radiography and traditional chest X-rays in the detection of pulmonary nodules
Original Article Comparison of dual energy subtraction chest radiography and traditional chest X-rays in the detection of pulmonary nodules Farheen Manji 1, Jiheng Wang 2, Geoff Norman 1, Zhou Wang 2,
More informationCharacteristics of Subsolid Pulmonary Nodules Showing Growth During Follow-up With CT Scanning
CHEST Original Research Characteristics of Subsolid Pulmonary Nodules Showing Growth During Follow-up With CT Scanning Haruhisa Matsuguma, MD ; Kiyoshi Mori, MD ; Rie Nakahara, MD ; Haruko Suzuki, MD ;
More informationSynchronous Triple Primary Lung Cancers: A Case Report
Case Report Thoracic Imaging http://dx.doi.org/10.3348/kjr.2014.15.5.646 pissn 1229-6929 eissn 2005-8330 Korean J Radiol 2014;15(5):646-650 Synchronous Triple Primary Lung Cancers: A Case Report Hyun Jung
More informationComparison of High-resolution CT Findings between Miliary Metastases and Miliary Tuberculosis 1
Comparison of High-resolution CT Findings between Miliary Metastases and Miliary Tuberculosis 1 Chan Sung Kim, M.D., Ki-Nam Lee, M.D., Jin Hwa Lee, M.D. Purpose: To compare the findings of high-resolution
More informationtomography Assessment of bronchiectasis by computed Reid' into three types-cystic, varicose, andcylindrical.
Thorax 1985;40:920-924 Assessment of bronchiectasis by computed tomography IM MOOTOOSAMY, RH REZNEK, J OSMAN, RSO REES, MALCOLM GREEN From the Departments of Diagnostic Radiology and Chest Medicine, St
More informationDiffuse high-attenuation within mediastinal lymph nodes on non-enhanced CT scan: Usefulness in the prediction of benignancy
Diffuse high-attenuation within mediastinal lymph nodes on non-enhanced CT scan: Usefulness in the prediction of benignancy Poster No.: C-1785 Congress: ECR 2012 Type: Authors: Keywords: DOI: Scientific
More informationDoes the lung nodule look aggressive enough to warrant a more extensive operation?
Accepted Manuscript Does the lung nodule look aggressive enough to warrant a more extensive operation? Michael Kuan-Yew Hsin, MBChB, MA, FRCS(CTh), David Chi-Leung Lam, MD, PhD, FRCP (Edin, Glasg & Lond)
More informationI8 COMPLETION INSTRUCTIONS
The I8 Form is completed for each screening exam at T0, T1, and T2. At T0 (baseline), the I8 Form documents comparison review of the baseline screen (DR Form) with any historical images available. At T1
More informationManagement of Multiple Pure Ground-Glass Opacity Lesions in Patients with Bronchioloalveolar Carcinoma
ORIGINAL ARTICLE Management of Multiple Pure Ground-Glass Opacity Lesions in Patients with Bronchioloalveolar Carcinoma Hong Kwan Kim, MD,* Yong Soo Choi, MD,* Jhingook Kim, MD, PhD,* Young Mog Shim, MD,
More information